In summary, our study demonstrates that Φ‐NGAL macrophage cell therapy has a therapeutic effect on DKD in diabetic mice probably by modulation of the renal inflammatory response caused by the diabetic milieu. This evidence concerns the gene LCN2 and diabetic kidney disease.